<DOC> 
<DOCNO>1040727_business_story_3547447.utf8</DOCNO> 
<TEXT> 

The Telegraph - Calcutta : Business
 Tuesday, July 27, 2004 				 Wockhardt mulls American listing 
 OUR BUREAU																								Mumbai, July 26: Pharmaceutical major Wockhardt Limited is planning to get listed on the American bourses. The board has approved a proposal to acquire pharmaceutical companies and businesses in Europe to the tune of $100 million.																								Wockhardt is fully committed to expand its business in the European Union through internal growth as well as acquisitions, chairman Habil Khorakiwala said in a release here today after the board meeting in Wrexham, UK.																								The boards approval to invest $100 million is a major step, he added.																								Wockhardt said the European Union has emerged as the companys largest market. Earlier this year, it had established Wockhardt USA Inc to spearhead the generics business in the US market.																								In order to give a thrust to the European business, the company is taking steps to integrate the operations of Wockhardt UK and Esparma Germany with Wockhardts global supply chain. Simultaneously, Wockhardt USA is working with the firms scientists in India to launch a host of products in the US, Khorakiwala said.																								European Union and the US together accounted for as much as 80 per cent of the companys international business, he added.																								Wockhardt group has reported a 43.1 per cent rise in consolidated net profit at Rs 50.1 crore for the second quarter ended June 30, 2004 compared with Rs 35 crore posted in the corresponding previous quarter.																								Income from operations rose to Rs 289.2 crore against Rs 211 crore in the year-ago period, the drug major said.																								For the first half ended June, the companys net profit and income from operations stood at Rs 94.6 crore (Rs 43.2 crore) and Rs 577.5 crore (Rs 373 crore) respectively.																								The firms international business grew by 87 per cent in the April-June period. Also during the quarter, the company received USFDA approval of for its sterile bulk drug and formulation facilities in the very first inspection. 																								Wockhardt was active in new drug discovery with three new molecules undergoing trials in India, it added. 
</TEXT> 
</DOC>